BIOMAT Database Logo BIOMAT Database Logo

Polymorphic light eruption. 2003

William D Tutrone, and Candace Thornton Spann, and Noah Scheinfeld, and Vincent A Deleo
Department of Dermatology, St. Luke's-Roosevelt Hospital Center, New York, New York 10025, USA.

Polymorphic light eruption (PMLE) is the most common photodermatosis. It is typically characterized by nonscarring, pruritic, erythematous papules, plaques, or vesicles on sun-exposed skin that develop 30 minutes to several hours after sun exposure. The eruption may persist for a few hours to as long as 2 weeks. Females are affected two to three times more often than males. PMLE has been reported in all races, but tends to affect fair-skinned individuals with Fitzpatrick skin types I-IV most commonly. The pathogenesis of PMLE has been difficult to define, although it appears to be an immune-mediated delayed-type hypersensitivity reaction. Abnormalities of arachidonic acid metabolism and a possible correlation with lupus are other theories that are reviewed. Treatment options have been explored extensively. While "hardening" or desensitization of the skin through repeated irradiation seems to be the most effective, therapeutic options such as sun avoidance/sun protection, oral carotenoids, and antimalarials are also considered.

UI MeSH Term Description Entries
D008180 Lupus Erythematosus, Systemic A chronic, relapsing, inflammatory, and often febrile multisystemic disorder of connective tissue, characterized principally by involvement of the skin, joints, kidneys, and serosal membranes. It is of unknown etiology, but is thought to represent a failure of the regulatory mechanisms of the autoimmune system. The disease is marked by a wide range of system dysfunctions, an elevated erythrocyte sedimentation rate, and the formation of LE cells in the blood or bone marrow. Libman-Sacks Disease,Lupus Erythematosus Disseminatus,Systemic Lupus Erythematosus,Disease, Libman-Sacks,Libman Sacks Disease
D009536 Niacinamide An important compound functioning as a component of the coenzyme NAD. Its primary significance is in the prevention and/or cure of blacktongue and PELLAGRA. Most animals cannot manufacture this compound in amounts sufficient to prevent nutritional deficiency and it therefore must be supplemented through dietary intake. Nicotinamide,Vitamin B 3,Vitamin PP,3-Pyridinecarboxamide,Enduramide,Nicobion,Nicotinsäureamid Jenapharm,Papulex,Vitamin B3,3 Pyridinecarboxamide,B 3, Vitamin,B3, Vitamin,Jenapharm, Nicotinsäureamid
D010787 Photosensitivity Disorders Abnormal responses to sunlight or artificial light due to extreme reactivity of light-absorbing molecules in tissues. It refers almost exclusively to skin photosensitivity, including sunburn, reactions due to repeated prolonged exposure in the absence of photosensitizing factors, and reactions requiring photosensitizing factors such as photosensitizing agents and certain diseases. With restricted reference to skin tissue, it does not include photosensitivity of the eye to light, as in photophobia or photosensitive epilepsy. Actinic Reticuloid Syndrome,Dermatitis, Actinic,Photodermatitis,Chronic Actinic Dermatitis,Photosensitization,Actinic Dermatitides,Actinic Dermatitides, Chronic,Actinic Dermatitis,Actinic Dermatitis, Chronic,Actinic Reticuloid Syndromes,Chronic Actinic Dermatitides,Dermatitides, Actinic,Dermatitides, Chronic Actinic,Dermatitis, Chronic Actinic,Disorder, Photosensitivity,Disorders, Photosensitivity,Photodermatitides,Photosensitivity Disorder,Reticuloid Syndrome, Actinic,Reticuloid Syndromes, Actinic,Syndrome, Actinic Reticuloid,Syndromes, Actinic Reticuloid
D011701 PUVA Therapy Photochemotherapy using PSORALENS as the photosensitizing agent and ultraviolet light type A (UVA). Psoralen Ultraviolet A Therapy,Therapy, PUVA,PUVA Therapies,Therapies, PUVA
D003879 Dermatologic Agents Drugs used to treat or prevent skin disorders or for the routine care of skin. Agent, Dermatologic,Agent, Dermatological,Agents, Dermatologic,Dermatologic Agent,Dermatological Agents,Agents, Dermatological,Dermatological Agent
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D006886 Hydroxychloroquine A chemotherapeutic agent that acts against erythrocytic forms of malarial parasites. Hydroxychloroquine appears to concentrate in food vacuoles of affected protozoa. It inhibits plasmodial heme polymerase. (From Gilman et al., Goodman and Gilman's The Pharmacological Basis of Therapeutics, 9th ed, p970) Hydroxychlorochin,Oxychlorochin,Oxychloroquine,Hydroxychloroquine Sulfate,Hydroxychloroquine Sulfate (1:1) Salt,Plaquenil
D013473 Sunscreening Agents Chemical or physical agents that protect the skin from sunburn and erythema by absorbing or blocking ultraviolet radiation. Sunscreen,Sunscreens,Agents, Sunscreening
D015897 Comorbidity The presence of co-existing or additional diseases with reference to an initial diagnosis or with reference to the index condition that is the subject of study. Comorbidity may affect the ability of affected individuals to function and also their survival; it may be used as a prognostic indicator for length of hospital stay, cost factors, and outcome or survival.
D016718 Arachidonic Acid An unsaturated, essential fatty acid. It is found in animal and human fat as well as in the liver, brain, and glandular organs, and is a constituent of animal phosphatides. It is formed by the synthesis from dietary linoleic acid and is a precursor in the biosynthesis of prostaglandins, thromboxanes, and leukotrienes. (all-Z)-5,8,11,14-Eicosatetraenoic acid,Arachidonic Acid, (all-Z)-Isomer, 1-(14)C-Labeled,Arachidonic Acid, (all-Z)-isomer, 3H-Labeled,Arachidonic Acid, Ammonium Salt, (all-Z)-Isomer,Arachidonic Acid, Cerium Salt, (all-Z)-Isomer,Arachidonic Acid, Cesium Salt, (all-Z)-Isomer,Arachidonic Acid, Lithium Salt, (all-Z)-Isomer,Arachidonic Acid, Potassium Salt, (all-Z)-Isomer,Arachidonic Acid, Sodium Salt,Arachidonic Acid, Sodium Salt, (all-Z)-Isomer,Arachidonic Acid, Zinc Salt, (all-Z)-Isomer,Sodium Arachidonate,Vitamin F,Arachidonate, Sodium

Related Publications

William D Tutrone, and Candace Thornton Spann, and Noah Scheinfeld, and Vincent A Deleo
Polymorphic light eruption sine eruption.
January 1988, The British journal of dermatology,
William D Tutrone, and Candace Thornton Spann, and Noah Scheinfeld, and Vincent A Deleo
Polymorphic Light Eruption.
March 1947, Proceedings of the Royal Society of Medicine,
William D Tutrone, and Candace Thornton Spann, and Noah Scheinfeld, and Vincent A Deleo
Polymorphic light eruption.
November 1970, Archives of dermatology,
William D Tutrone, and Candace Thornton Spann, and Noah Scheinfeld, and Vincent A Deleo
Polymorphic light eruption.
October 2017, The Medical journal of Australia,
William D Tutrone, and Candace Thornton Spann, and Noah Scheinfeld, and Vincent A Deleo
Polymorphic light eruption.
July 1960, The British journal of dermatology,
William D Tutrone, and Candace Thornton Spann, and Noah Scheinfeld, and Vincent A Deleo
Polymorphic light eruption.
October 1990, Photodermatology, photoimmunology & photomedicine,
William D Tutrone, and Candace Thornton Spann, and Noah Scheinfeld, and Vincent A Deleo
Polymorphic light eruption reassessed.
March 2004, Archives of dermatology,
William D Tutrone, and Candace Thornton Spann, and Noah Scheinfeld, and Vincent A Deleo
Treatment of polymorphic light eruption.
October 2003, Photodermatology, photoimmunology & photomedicine,
William D Tutrone, and Candace Thornton Spann, and Noah Scheinfeld, and Vincent A Deleo
Contact UVA polymorphic light eruption.
March 1984, Contact dermatitis,
William D Tutrone, and Candace Thornton Spann, and Noah Scheinfeld, and Vincent A Deleo
Polymorphic light eruption in childhood.
December 1985, Clinical pediatrics,
Copied contents to your clipboard!